Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial

INTRODUCTION: Women-controlled HIV prevention technologies that overcome adherence challenges of available daily oral pre-exposure prophylaxis and give women a choice of options are urgently needed. Broadly neutralising monoclonal antibodies (bnAbs) administered passively may offer a valuable non-an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahomed, Sharana, Garrett, Nigel, Potloane, Disebo, Sikazwe, Izukanji T, Capparelli, Edmund, Harkoo, Ishana, Gengiah, Tanuja Narayansamy, Zuma, Nonhlanhla Yende, Osman, Farzana, Mansoor, Leila, Archary, Derseree, Myeni, Nqobile, Radebe, Precious, Samsunder, Natasha, Doria-Rose, Nicole, Carlton, Kevin, Gama, Lucio, Koup, Richard A, Narpala, Sandeep, Serebryannyy, Leonid, Moore, Penny, Williamson, Carolyn, Pozzetto, Bruno, Hankins, Catherine, Morris, Lynn, Karim, Quarraisha Abdool, Abdool Karim, Salim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462944/
https://www.ncbi.nlm.nih.gov/pubmed/37640457
http://dx.doi.org/10.1136/bmjopen-2023-076843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462944/
https://www.ncbi.nlm.nih.gov/pubmed/37640457
http://dx.doi.org/10.1136/bmjopen-2023-076843

Ejemplares similares